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“Where the common disease communities bring opportunities of scale, the heritable
disease community brings insights from detail and experience. Both are concerned
with personalized medicine and should work together.”
-- Burton et al. 2011 [1]
1. CHANGING MINDSETS AND THINKING BEYOND BORDERS
1.1. Rise of Collective Innovation
The Millennium Summit in 2000 established the Millennium Development Goals (MDGs),
which were agreed upon by 193 countries and 23 international organizations to combat
extreme poverty and other pressing global priorities for human development. In the
December 2011 issue of CPPM, Borda-Rodriguez and Huzair present an analysis of the
close ties and synergies among the MDGs, pharmacogenomics and personalized medicine
[2]. Notably, MDGs promote the creation of collective innovation, a concept with both
substantive and instrumental pertinence for the personalized medicine R&D that is currently
undergoing rapid globalization. The ethos for collective innovation in global health is also
embodied in the Paris Declaration on Aid Effectiveness, endorsed in 2005 by more than 100
signatories, including donor and developing country governments, regional development
banks and international aid agencies [3].
Launched in 2008, CPPM is a peer-reviewed integrated forum for pharmacogenomics and
personalized medicine as seen through the lens of global public health [4], with particular
attention to emerging applications in developing countries [5–7]. If the field of personalized
medicine is to equitably expand to low and middle income countries (LMICs) to address
neglected tropical diseases, tuberculosis, HIV/AIDS, malaria [5] and the current global
epidemic of noncommunicable diseases (NCDs) [8], significant changes in mindsets are
necessary [7, 9, 10].
The traditional Westphalian model of independent sovereign nation states does not
adequately recognize the complex interdependencies in global governance for health [9] or
the need to think about genomics beyond national borders [7, 11–13]. Moreover, the
pharmacogenomics community has been “on pause” in incorporating critical social sciences
and humanities research [14], while other emerging postgenomics data-intensive fields such
as nanotechnology have been appropriately on “fast forward” [15, 16]. Creating healthy and
sustainable modern societies in the 21st century requires “integrated knowledge ecosystems”
with contributions from all sectors of science and society:
Discussing the state of health at the beginning of the 21st century is not dissimilar
to discussing the state of the environment. Both are in crisis and run counter to the
notion of sustainable wellbeing, both focus around the ways of life that have
developed in our societies and both indicate that significant changes are required at
the level of policy and of society...Both our extensive knowledge about what
creates health, as well as the exponentially rising rates of chronic disease, obesity
and mental health problems, indicate that we need to shift course and apply a
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radically new mindset to health…Some warning voices state that the present
generation of children – born at the turn of the century – might be the first to have a
lower life expectancy than their parents. After the extraordinary gains in health and
longevity over the last 100 years, such a development would indeed represent a
phenomenal failure…Clearly if health is created by factors outside the remit of the
traditional health sector then the creation of a healthy society needs commitment
and action from all sectors of government, new partnerships for health, and
citizens’ participation [17].
The above insights describe precisely what is needed to transform the “one-scientist-
oneproject paradigm” that has hitherto prevailed throughout the 20th century towards
crossdisciplinary collaborative science in the 21st century [7, 18–20]. Collective innovation
offers the promise of novel diagnostics for complex diseases and single gene disorders, as
well as customized drug therapies, vaccines, cell-based therapies and nutrition [7].
Diagnostics are now being developed by innovators well beyond the industrialized countries
of the North [5–7, 21]. In particular, the Asia-Pacific region is rapidly emerging, owing to
substantial investments in dataintensive life sciences research [6, 7, 22]. A recent study on
the globalization of science found, using quantitative indicators, that the current growth rate
for state-level research funding in China greatly exceeds that in the US and the European
Union (EU) [23, 24].
The Human Variome Project (HVP), an incorporated and globally inclusive charitable body
headquartered at the University of Melbourne, Australia, is a large-scale international
consortium for collective innovation on the critical path to novel diagnostics [11, 25]. The
HVP offers the promise to vastly impact and inform the continuum from disease prevention
and diagnosis to personalized rational therapeutics. As a global collective initiative in
partnerships with individual country genetic societies, the HVP will collect and curate all
human genetic variation effecting human disease. The endorsement in 2011 of the HVP by
the United Nations Educational, Scientific and Cultural Organization (UNESCO) [25],
together with the recent pledge by the Chinese Government of US$300 million to establish a
new institute to directly contribute to the efforts of the HVP, brought about a renewed
enthusiasm for novel diagnostics as well as formidable expectations for global public health
and personalized healthcare.
Diseases with a strong heritable component (often referred to as Mendelian or single gene
disorders) provide many potential avenues for novel diagnostics on the path to global
personalized medicine [1, 26]. Indeed, the Online Mendelian Inheritance in Man (OMIM)
database indicates that there are 1638 autosomal phenotypes for which the molecular basis is
unknown [13]. Historically, such disorders have been neglected in discussions on
personalized medicine, perhaps because of their rarity and the difficulty in identifying the
underlying genes and mutations [1, 13]. The Rare Disease Consortium for Autosomal Loci
(RaDiCAL) led by McGill University in Canada is a recent effort to address precisely this
knowledge gap [13] on putative autosomal recessive diseases. The RaDiCAL consortium
takes a whole exome (or whole genome) approach and gives priority to autosomal recessive
conditions so as to yield far fewer false positive hits when searching for either a
homozygous deleterious mutation or two deleterious mutations in a single gene.
Postgenomics personalized medicine is experiencing a “data deluge” from emerging high-
throughput technologies and a myriad of sensors and exponential growth in electronic
records. Data-driven, data-intensive science (referred to herein as “data-enabled science”)
was originally proposed by Jim Gray and colleagues as the Fourth Paradigm of scientific
inquiry [22]. It builds on and greatly expands the three precedent paradigms – theory,
experimentation and simulation (modeling) [22]. Data-enabled science is defined by the
National Science Foundation (NSF) as a new research paradigm that firmly depends on a
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data commons [27] or “infrastructure science” and is inseparable from the classic “discovery
science” [22, 28]. The data-enabled science community recognized that shared problems
such as the current transition of bioinformatics to clouds demand collective solutions and
moved to establish the Data Enabled Life Sciences Alliance (DELSA) with the vision of
sustainable and shared access to data, knowledge and tools for 21st century postgenomics
life sciences [29].
As we begin to turn towards collective innovation in postgenomics R&D, this editorial
analysis provides an overview of the HVP, RaDiCAL and DELSA that share a global ethos
for collective innovation in data-enabled sciences. In the spirit of collective research
infrastructure capacity building for postgenomics novel diagnostics, we present a survey of
the insights and expectations from the leading experts in global regions where disease
burdens stand to benefit from the HVP, RaDiCAL and DELSA. Developing countries, in
particular, have a significant role to play in the elucidation of the genetic basis of both
common and rare disorders, providing an invaluable resource of cases due to large family
sizes, consanguinity, and potential founder effects. Research in any one country can also
inform the genomics healthcare for individuals and family groups in diaspora in other
countries. We also wish to note the generation of a new initiative, the International Rare
Disease Research Consortium (IRDiRC) [30], whose main thrust is to develop therapeutics
and diagnostics for rare disorders with a smaller input into global registries.
We conclude the editorial by underscoring that the HVP, RaDiCAL and DELSA attest to the
ever increasing diversity in the “ecology of collective innovation”, which is essential for
discovery of truly novel diagnostics that can benefit global personalized medicine and public
health.
2. THE HUMAN VARIOME PROJECT (HVP)
The global community needs total annotation of the human genome and it could still be
decades before this is complete. The Human Variome Project [25] was initiated to collect all
variations effecting human disease. The project was launched at a World Health
Organization (WHO)-hosted meeting in Melbourne, Australia in 2006 by representatives
from the WHO, the UNESCO, European Commission, Organisation for Economic Co-
operation and Development (OECD), March of Dimes, major databases, 30 countries, and
world experts [31]. Recommendations from this inaugural meeting were subsequently
published [32]. Most recently, the Human Variome Project has been incorporated as a
charitable body and the third Human Variome Project Meeting at Paris UNESCO
Headquarters [33] elected an interim scientific advisory committee and ratified a roadmap
[25].
The aim of the Human Variome Project is to facilitate the collection of all mutations
effecting human disease in all genes and from all countries, to link this to clinical and
phenotypic data, and to make the data freely and openly available for use in research and
patient care worldwide. The roadmap specifies a two-pronged approach to this collection.
The first approach is via gene/locus/disease specific databases (LSDBs). A number of
LSDBs have been in existence for many years, providing expert oversight and curation of
data associated with single genes or diseases. Existing databases must be encouraged to
grow and expand, while new databases need to be created to fill the gaps in genome
coverage. The second approach is via country-specific nodes, which are relatively novel and
which are needed for proper genetic healthcare, funding and strategy in each country [34]. In
the past, LSDBs usually focused on the first instance of a particular mutation, but there is a
need to collect each instance of a mutation for various reasons [34].
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Considerable progress has been made already by the HVP. This includes: (a) a pilot data
collection strategy and databasing by the inherited colon cancer community (InSiGHT) [35]
with other areas of biology/disease progressing; (b) the launch of the Human Variome
Project Australian Node (www.hvpaustralia.org.au) on April 1, 2011 as a pilot to collect all
data within a country and to provide software and strategy to those who need it; (c) 12
countries so far that have agreed to set up country nodes; (d) China agreeing to fund a
substantial amount of the project (see above); (e) the Project being granted the status of
‘Non Governmental Organization (NGO) in Operational Relations with UNESCO’; and (f)
the holding of international forums and lectures in 16 countries since 2006.
A major meeting focusing on new international collaborations will be held in Beijing on
December 8–12, 2011 and the fourth HVP meeting will be held at UNESCO Headquarters
in Paris on June 11–15, 2012 [25]. A global call has been made to encourage all to join the
HVP [25].
3. RARE DISEASE CONSORTIUM FOR AUTOSOMAL LOCI (RaDiCAL)
RaDiCAL is an attempt by researchers, initially based in the Department of Human Genetics
at McGill University in Montreal, Quebec, Canada, to fast track gene discovery for
autosomal diseases using approaches such as exome and whole genome sequencing [13].
The thought behind RaDiCAL is that since many in the scientific and medical communities
are driven by personal career and academic motives, there is a need to stimulate a new
approach that will result in rapid discoveries that will immediately benefit patients. The goal
of RaDiCAL is to find as many genes as possible as quickly as possible for the purpose of
better diagnosis and genetic counseling. The hope is to work with clinical colleagues around
the world to collect a single well-characterized proband for each autosomal recessive disease
for which the gene is not known. Importantly, the limiting factor in this approach is the
clinical diagnosis and not the molecular biology. All gene assignments would have to be
independently validated by looking at additional patients with the same clinical condition.
The plan is to publish or post candidate genes for each disease quickly and without
functional validation. In addition, there would be no attempt to look at known disease genes
in the samples from patients that are not candidates for the diseases in question. How these
candidates will be made accessible to the community at large remains unclear. Either a
journal or society will champion this approach or it will be necessary to create and maintain
a centralized database that would simply post candidate genes. The arrival of data-enabled
sciences and the increasing recognition of “data” and “data citation” as legitimate units of
microattribution (e.g., as a complement to classic journal article citations) for scientific
credit and academic promotion, could catalyze and transform upstream discovery initiatives
such as RaDiCAL.
4. DATA-ENABLED LIFE SCIENCES ALLIANCE (DELSA)
The data-enabled science paradigm is a departure from traditional hypothesis-driven life
science research. Because it opens up new avenues of scientific exploration that do not rely
on prior assumptions on disease pathophysiology or drug action, the paradigm thus paves
the way for innovative solutions to current problems in life sciences, medicine and global
health. In this era of data-enabled science, life scientists produce diverse, multifaceted data
at an unprecedented and accelerated pace that is too often unmatched by the availability of
adequate cyberinfrastructure capacity and real-life policies to govern its use. In September
2010, the data-enabled community explored issues and challenges associated with these new
avenues [36] and in May 2011, the community established the DELSA with the vision of
advancing 21st century life sciences by moving from “one scientist-one project” to
“collective innovation”. Hosted by the Seattle Children’s Research Institute [29], co-
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founders are geographically distributed with research interests spanning an extensive array
of fields such as ecology, biodiversity, bioinformatics, pharmacogenomics,
pharmacoproteomics and sustainability sciences. DELSA also includes experts in computer
sciences, super-computing, data and cyberinfrastructure.
The data deluge the life sciences community currently faces is part of the Fourth Paradigm
of scientific inquiry [22]. This brings about a need for organizational and cultural changes in
addition to those changes/advances usually associated with a technical realm. These changes
will come about through a supporting ecosystem that includes: research funding agencies
and foundations in developed countries and LMICs; governments; academia; industry; and
publics. All must work together to build capacity for data-enabled life sciences infrastructure
and discovery. In particular, cloud-based and distributed computing technologies are some
of the salient focus areas for DELSA. Cloud computing offers the possibility of “on
demand” flexible computing that is of great relevance for global personalized medicine,
including in rural and resource-limited settings in LMICs. With cloud computing, 1000
computers used for one hour costs the same as one computer used for 1000 hours [29].
5. FROM CONSORTIA TO COLLECTIVE INNOVATION
Both frequent contacts between data/knowledge generators (e.g., scientists, technology
designers) and end-users (e.g., publics, policy-makers) and creating mechanisms between
supply and demand of knowledge and technology are necessary to move towards
responsible innovation in democratic societies [9, 10]. Hence, we present below expert
insights on the current situation in global regions, including developing countries, in relation
to collective innovation in data-enabled life sciences, and what we may anticipate ahead.
5.1. South Africa
South Africa is home to many distinct populations, displaying abundant genetic diversity but
also homogeneity due to founder effects [5]. While these populations, as those from other
sub-Saharan countries, have been largely underrepresented in genomics and postgenomics
research, international initiatives such as HVP, RaDiCAL, DELSA, as well as the Human
Heredity and Health in Africa (H3Africa) [37] can enable such research in Africa. South
Africa is already linked to the HVP through the InSiGHT group, who will pilot country-
specific collections for four colon cancer genes [38]. Furthermore, the country has a number
of established clinical genetic units that could participate in RaDiCAL, as first and second
generation sequencing facilities are now readily available locally for the characterization or
validation of candidate genes by whole exome or targeted re-sequencing. While the
establishment of biorepositories and bioinformatic expertise and networks are featuring
prominently on the agendas of H3Africa and the Southern African Human Genome Project
[39], the training and retraining of clinical geneticists and genetic counselors should also be
a high priority, as they are key role players in basic as well as translational research. The
commitment of local and national government to contribute to long-term sustainable funding
for research and translational services will thus have a significant impact on the long-term
success and impact of postgenomic research in South Africa [5, 40]. Future challenges will
be linking the genetic variations to more common and complex human diseases and traits,
and understanding the interaction of these variations with the different and unique
environmental conditions in Africa.
In the immediate term, the benefits of studies such as HVP and RaDiCAL will include the
more thorough characterization of southern African diversity through the analyses of whole
exome and genome data of population samples, and linking some of the genetic variants to
human Mendelian disorders. Efforts by DELSA to develop cyberinfrastructure and high-
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throughput analysis capacity, including the emerging cloud technologies, can potentially
extend the reach of genomics medicine to rural communities in the African continent.
5.2. United Arab Emirates and Other Arab States
In the United Arab Emirates, and more generally in other Arab countries, the highly
demanding data intensive field of collective genomics is mainly available in selected
research centers that are distributed over a vast geographical area including North Africa,
the Eastern Mediterranean, and the Gulf States. Some of the Arab countries, such as Tunisia,
Morocco and Lebanon, have integrated adequately into international collaborative networks,
but this engagement primarily centers on the implementation of advanced high-throughput
omics molecular technologies [41]. That is, postgenomics research in many Eastern
Mediterranean and Gulf States seems to be fuelled by collaborations at a downstream
clinical innovation level essentially targeting endogenous country-specific public health
needs, despite the wealth of technologies that are available for upstream discovery-oriented
postgenomics research in the region [12].
The capacity for collective innovation in genomics in the United Arab Emirates and Arab
countries can be developed by:
• coordinated transfer of know-how to local researchers as well as addressing the
serious imbalance in genomics R&D funding by local governments;
• accelerating development aid in genomics and personalized medicine, but with
careful consideration of the priorities of the recipient countries, and not only of the
donors (see also the editorial discussion in this issue of CPPM by Borda-Rodriguez
and Huzair) [2]; and
• comprehension of the importance of genomic applications for global public health
in LMICs (see the previous CPPM interview article by Muin J. Khoury) [4].
At the time of the publication of this editorial, nearly 979 conditions are known to cause
various forms of inherited disorders in Arab populations [42]. Of these, a large majority, 718
disorders, are associated with well-documented gene pathologies in other global
populations. Yet, population genomic analyses of almost half of these disorders have not
been carried out in the region and this represents a serious loss of a shallow infonome (a
term previously coined by a co-author of this editorial, Dr. G.O. Tadmouri, referring to the
total information gained by study of disease-causing variation) that may be remedied rapidly
by appropriate use of genomics tools. A promising trend, however, is that 71 disorders have
been clinically and genetically characterized over the last 12 years for the first time in Arab
families. Additionally, there are 261 inherited disorders that are almost exclusively
described in Arab families and the available knowledge is only confined to clinical studies
with no efforts to study their genetic etiologies. Deciphering the molecular pathologies of
these disorders, including many monogenic Mendelian diseases, will definitely result in
unearthing the deep infonome (i.e., the information gained by study of the total variome
content of a genome). The knowledge of the deep infonome will be even more attractive
when combined with large-scale studies aiming to map non-disease variome patterns in the
highly charged gene pool in Arab populations. The consortia for collective innovation
discussed in this editorial, the HVP, RaDiCAL and DELSA, are therefore in direct synergy
with the extant needs of genomics medicine and the resources presently available in the
United Arab Emirates and other Arab countries.
5.3. Egypt
A recent analysis of the scientific publication data from the Web of Science over the past 30
years (1980 – 2009) found that Asia’s share of world scientific output grew by 155%, while
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the Middle East, as a region, displayed a growth four times faster than at the world level
[43]. Egypt, ranked fourth in this recent report [43], is among the leading Middle Eastern
countries in scientific output. Out of the 16 Middle Eastern countries, Egypt is ranked third
by the H-index, with Israel and Turkey taking the first and second positions, respectively
[44]. Importantly, while the scientific contribution of Egypt relative to the rest of the Middle
East has slightly decreased, it steadily increased by more than three-fold in the category of
“Biochemistry, Genetics and Molecular Biology” over the past 15 years [44]. Moreover,
international collaboration is a major aspect of the Egyptian scientific output: about 40% of
all publications are contributed by authors from two or more countries; this number reaches
50% in the category “Biochemistry, Genetics, and Molecular Biology”.
In spite of this stupendous growth in Egyptian biochemical and genetics research, the
contributions to genome-wide studies are still restricted to scattered individual attempts,
mostly relying on international collaborations, where Egyptian researchers single-handedly
travel and carry out most of the experimental work abroad [45], or in collaboration with a
large regional institution such as the Red Sea Metagenomics Project (launched as a
collaboration between the American University in Cairo and King Abdullah University in
Saudi Arabia [46]).
5.4. Turkey
Turkey has a high rate of consanguineous marriages that is one of the major causes of
recessive diseases in the country. For example, in the southern population of Turkey, the
prevalence of consanguinity in rural areas is quite high, estimated to be around 40%, and is
associated, for example, with beta-thalassaemia major [47]. Because personalized medicine
has long been framed in the international arena rather narrowly around common complex
diseases, we wish to underscore that in countries such as Turkey with a high level of
consanguineous marriages, single gene and recessive disorders have great public health
significance; novel diagnostics can make an important contribution for early detection and
genetic counseling of vast numbers of families in Turkey. Hence, it will be important to
highlight the similarities between both common diseases and single gene diseases and that
both fall under the rubric of personalized medicine as indicated recently for the CPPM
readership by Burton et al. [1].
An inaugural conference on personalized medicine was held in Istanbul in 2009 with large
participation from scientists, patient interest groups and publics [48]. Among the Middle
Eastern countries, Turkey has recently ranked as second in scientific impact according to the
H-index, as noted above. Still, the much-needed global public health genomics lens [4] is
missing in Turkey as in many other LMICs. Incorporation of the ACCE public health
evidentiary framework to emerging R&D efforts for personalized healthcare in Turkey is
essential and would be a concrete way forward (see also discussion in Section 8) [4].
Regional capacity building efforts in genomics and personalized medicine, its integration
with genetic counseling, as well as education of scientists, healthcare professionals and
publics are underway at the Personalized Genomics Healthcare Center, Pharmvation-
BIGEM at Anadolu University in Eskişehir, Turkey. Incorporation of human genomics
variation in routine therapeutic drug monitoring and pharmacovigilance is an immediately
actionable priority area for Turkey.
5.5. India
India has the world’s second largest population, consisting of over 4500 communities with
vast human genetic/genomic variation. The tradition of consanguineous marriages is
common in certain communities, as are hereditary diseases. The most prominent single gene
disorders include hemophilia such as beta-thalassemia (with 4% prevalence), sickle cell
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anemia, cystic fibrosis and Wilson’s disease. To identify the carriers in the population and at
risk groups, screening programs have been initiated [49]. The Council of Scientific and
Industrial Research, along with seven research institutes, started the Indian Genome
Variation (IGV) project in 2003 to understand the inherent genetic variability of
subpopulations, identify SNPs in thousands of genes, construct haplotype maps and
determine functional consequence of genetic markers [50]. Furthermore, the IGV database
(IGVdb) project is documenting SNPs and repeat polymorphisms using highthroughput
platforms. The New Millennium Indian Technology Leadership and the National
Biotechnology Development Strategy have also been initiated. The Department of
Biotechnology has constituted a task force on the Human Genetics and Genome Analysis,
which, among several initiatives, have established several units for genetic diagnosis and
counseling services.
It is interesting to note that although India could not participate in the Human Genome
Project extensively, the IGV and other initiatives outlined above illustrate the growing
investments in genomics and postgenomics R&D in the country. Insofar as the HVP,
RaDiCAL and DELSA are concerned, notable priority data-enabled science fields in India
include proteomics, pharmacoproteomics and nanoproteomic technologies [6]. Indeed, in
2005, Dr. Abdul Kalam, the former President of India, aptly observed that “India has the
potential to tap research opportunities in proteomics and biochips to help understand the
biological processes and treat diseases. This is possible even though the country has missed
the opportunity to partner in the Human Genome Project” [6]. The Indian Institute of
Technology Bombay and various other leading centers and universities in India have
developed extensive expertise in the field of pharmacoproteomics, proteomics and
nanotechnology. We refer the readers to the editorial analysis in the September issue of
CPPM where we published a detailed “innovation map” of proteomics and
pharmacoproteomics in India with a list of “hot spots” [6].
5.6. Sri Lanka
The island-state of Sri Lanka is situated closely to the Indian subcontinent. While there are a
very limited number of experts in molecular genetics in the country, public health genomics
services are necessary for population health in Sri Lanka, particularly to better understand
the epidemiology and transmission of life-threatening common tropical infections such as
dengue hemorrhagic fever in the Indian subcontinent as well as globally. However, aid and
development agencies have unfortunately not kept Sri Lanka in their priority list thus far,
despite a recent rise in congenital anomalies and NCDs. In response to the changing
epidemiology of disease burden in the country, national health policy is being targeted
towards the common causes of neonatal and infant deaths, tropical diseases and NCDs.
Molecular genetic/cytogenetic testing for human diseases is available from the private sector
and state institutions for a large number of conditions in Sri Lanka. There are three state-of-
the-art molecular technology units attached to university centers geared towards developing
new diagnostics and performing research in molecular genetics, and a cancer screening
center offering advanced care from initial risk assessment to appropriate screening for
cancer. At present, data on the prevalence of genetic diseases and associated genetic markers
are limited. Population-based prevalence studies have been done only for genetic conditions
where there is a known high prevalence in a particular area, for example, thalassaemia in the
Kurunegala district, or in the case of Down’s syndrome. Equity of access to genetic tests and
accreditation of genetic laboratories remain very problematic in Sri Lanka. The Sri Lanka
Accreditation Board has recently started the process of voluntary accreditation of state and
private laboratories offering diagnostic investigations in the country.
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With the end of the civil war in 2009, Sri Lanka is an important context for global health
practitioners for post-war capacity building in health R&D that is informed by data-enabled
sciences such as genomics and proteomics. The Sri Lankan Personal Genome Project is a
noteworthy and timely development in this regard [51].
6. BEYOND TECHNOLOGY
6.1. Open Source and Collaborative Knowledge Innovation Platforms
Despite the great successes achieved through genomics and related omics sciences, the field
suffers from a “transfer problem”, whereby its important pool of fundamental scientific
knowledge has not materialized in concrete applications. Various reasons have been
provided to explain this disappointing outlook, including biotechnology patent thickets,
university business models focused on a narrow commercialization framework, inefficient
regulatory approval processes, and overly constraining material transfer agreements [52, 53].
Promising avenues to solve this transfer problem could be based on the open source model
implemented through collaborative knowledge innovation platforms (e.g., crowdsourcing,
expert sourcing, cloud computing, social networking technologies). Their potential benefits,
though too soon to empirically evaluate, are considerable and include: promoting the
interoperability and harmonization of research platforms and tools, reducing financial risks,
democratizing access to innovation, preventing harmful duplication of research, and
facilitating the technology transfer process. Nonetheless, shifting from a classic
commercialization and individual-centered model of innovation to one that stresses
collective innovation, transparency and collaboration requires an acknowledgement of more
than just the ensuing (and obvious) technical and economic changes. It also requires an
exploration of the ability of LMICs to have the necessary IT infrastructure to access openly
shared data and actively participate in collaborations, the nature of the “informed” consent
provided by participants for open research, the role of ownership and commercialization of
genomic data, and the ability to uphold the duty of confidentiality and respect of
participants’ privacy. As postgenomic era science advances in its march towards collective
innovation to create novel diagnostics, democratize omics research and move from silos to
systems, we need to consider that open source, along with collaborative knowledge
innovation platforms, will play an essential role.
Since the HVP, RaDiCAL and DELSA are international large-scale initiatives, much can be
learned from the experience of population biobanks, in addition to the open source model
described above. For example, the Public Population Project in Genomics (P3G) is a not-for-
profit international consortium that aims to provide the international population genomics
community with access to tools and resources for biobanks to encourage collaboration
between researchers and biobankers, promote harmonization of information and optimize
the design, set-up and research activities of population-based biobanks [54]. Due to their
global nature, the collective innovation cases discussed in this editorial, as well as the policy
infrastructure (e.g., universal consent, open/controlled access, etc.) of future biobanks in
LMICs, can build on such publicly available tools.
7. THE DARK SIDE OF THE MOON: HOW DO PEOPLE ACTUALLY
COLLABORATE?
7.1. A Lesser-Known Side of Collective Innovation: Complex Collaboration Across
Knowledge Boundaries
It is interesting to note that we know very little about how individuals and stakeholder
groups are organizing themselves in the practice of data-enabled sciences, ways in which
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collaborations (e.g., cooperation, competition, pre-competitive collaboration) are developed,
sustained or devolve; what human values guide and inform the knowledge ecologies
emergent from collective innovation; and ultimately, how knowledge is created, transformed
and transferred between innovators and users. That is, the large-scale collective innovation
projects described in this editorial require not only the collection of genomic/proteomic and
human variome data on a world-wide scale but also an understanding of its social science
and humanities dimensions. As we move from a science where data collection was an
essential locus of the scientific endeavor to one where data collection is automated or at least
made easier and is available in digital form, there is a need to understand the new
collaborative possibilities that emerge.
It is our contention that traditional modes of knowledge sharing, such as international
meetings, pre-planned teams, and the traditional review process are possibly becoming
constraints on the collaboration needed to bring the Fourth Paradigm of scientific inquiry to
fruition. Current research in the organizational sciences has developed important insights on
how complex collaboration can be managed. It begins with a recognition that complex
collaboration is needed when knowledge crosses organizational or national boundaries,
when those involved have differences in methods, research practices, ontologies, human
values and epistemologies (i.e., ways of knowing). Further, because the knowledge is
typically produced in a local context within a specific community of practice, knowledge is
hard to transfer across boundaries and combine effectively [55–57]. Therefore, we suggest
that clear attention to complex collaboration is needed in order to make this new form of
research, i.e., data-enabled sciences for collective innovation, successful. Much can be
learned from adapting basic organizing principles, norms, and rewards from collective
action [58].
7.2. Collaborating with Publics in LMICs
In order to move ahead for global pharmacogenomics and personalized medicine, we need
to work with the public(s) in developed countries and LMICs, recalling that experts, too, are
part of the publics. Each community within a country or region may have different priorities
with respect to the major infectious diseases (malaria, tuberculosis and HIV/AIDS),
neglected tropical diseases (helminth infections), NCDs (cardiovascular diseases, cancer,
diabetes and chronic lung diseases) [8], and maternal, reproductive and mental health. These
priorities will need to be determined by the aid recipient countries to identify the solutions
that are required in the short-term versus the long-term while in parallel guiding the R&D
funding directions and development of new diagnostic tests for personalized healthcare for
each community. Setting these priorities collaboratively will also encourage transparency
and accessibility of genomics research findings for community members and directly
contribute to the measurement of health outcomes in postgenomics personalized medicine.
8. EVIDENTIARY FRAMES FOR DATA EVALUATION
In this issue of CPPM, Ptolemy describes the extant difficulties in translation of putative
biomarkers into a routine clinical setting [59]. To this end, those within the public health
genomics community have deployed the ACCE framework [4]. This framework respectively
evaluates the: (a) analytical validity, (b) clinical validity, (c) clinical utility and (d) ethical,
legal and social implications of a genetic test and/or putative biomarker. Through the
implementation of this evidentiary frame (which has a strong public health lens), researchers
would not only be able to challenge the validity of their data, but also objectively determine
the true clinical utility of a derived result, including its benefit to global society.
Including the experimental and public health tenets, such as those embodied in the ACCE
framework, in the global consortia from their outset, we can ensure that the massive
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amounts of data obtained from global collective innovation efforts are not only valid, but
also truly applicable and appropriate for their stated public health and societal goals.
CONCLUDING REMARKS
While an editorial analysis cannot provide the possibility to cover all global regions, we trust
that the original synthesis presented herein crucially informs future debates on global
personalized medicine, including the often-neglected views and advances from developing
countries. Recent applications of collective open-source genomics analysis, data release and
crowdsourcing approaches [60, 61] support the notion that the Fourth Paradigm of data-
enabled science has much to offer personalized medicine and novel diagnostics. We
therefore express our collective optimism that this new era will benefit global society in both
developed and developing countries.
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